1. Home
  2. AKRO vs GNL Comparison

AKRO vs GNL Comparison

Compare AKRO & GNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • GNL
  • Stock Information
  • Founded
  • AKRO 2017
  • GNL 2011
  • Country
  • AKRO United States
  • GNL United States
  • Employees
  • AKRO N/A
  • GNL N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • GNL Real Estate Investment Trusts
  • Sector
  • AKRO Health Care
  • GNL Real Estate
  • Exchange
  • AKRO Nasdaq
  • GNL Nasdaq
  • Market Cap
  • AKRO 2.4B
  • GNL 2.1B
  • IPO Year
  • AKRO 2019
  • GNL N/A
  • Fundamental
  • Price
  • AKRO $32.38
  • GNL $7.45
  • Analyst Decision
  • AKRO Strong Buy
  • GNL Buy
  • Analyst Count
  • AKRO 7
  • GNL 5
  • Target Price
  • AKRO $43.20
  • GNL $9.83
  • AVG Volume (30 Days)
  • AKRO 554.0K
  • GNL 1.2M
  • Earning Date
  • AKRO 11-08-2024
  • GNL 11-06-2024
  • Dividend Yield
  • AKRO N/A
  • GNL 14.60%
  • EPS Growth
  • AKRO N/A
  • GNL N/A
  • EPS
  • AKRO N/A
  • GNL N/A
  • Revenue
  • AKRO N/A
  • GNL $812,621,000.00
  • Revenue This Year
  • AKRO N/A
  • GNL N/A
  • Revenue Next Year
  • AKRO N/A
  • GNL N/A
  • P/E Ratio
  • AKRO N/A
  • GNL N/A
  • Revenue Growth
  • AKRO N/A
  • GNL 102.00
  • 52 Week Low
  • AKRO $13.86
  • GNL $6.52
  • 52 Week High
  • AKRO $37.00
  • GNL $10.19
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 55.64
  • GNL 30.12
  • Support Level
  • AKRO $31.12
  • GNL $7.61
  • Resistance Level
  • AKRO $35.11
  • GNL $8.16
  • Average True Range (ATR)
  • AKRO 1.74
  • GNL 0.20
  • MACD
  • AKRO 0.11
  • GNL -0.02
  • Stochastic Oscillator
  • AKRO 53.31
  • GNL 0.68

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail ; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.

Share on Social Networks: